Efficacy of adding Glucose Co-transporter 2 -Inhibitors in Treatment of Non-Valvular Paroxysmal Atrial Fibrillation | ||
| Aswan University Medical Journal | ||
| Article 14, Volume 5, Issue 3, September 2025, Pages 126-134 PDF (546.57 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/aumj.2025.372855.1221 | ||
| Authors | ||
| Esraa Abozied Abdelaziem* ; Ramadan G Mohamed; Nageh Mohamed Mahmoud; Aml Mohamed Soliman | ||
| Department of Cardiology, Faculty of Medicine, Aswan University | ||
| Abstract | ||
| Background: In individuals with type 2 diabetes mellitus, SGLT2 inhibitors have been demonstrated to lower blood pressure, decrease weight, improve left ventricular remodeling, and decrease hospitalization for heart failure and cardiovascular death. Objectives: The aim of this study was to evaluate the efficacy of SGLT2 inhibitors on the AF cardiovascular outcome. Methodology: This single-blinded randomized controlled trial was carried out on 60 cases with non-valvular paroxysmal atrial fibrillation at the cardiology department, Aswan University Hospitals. Results: the change in LAD% and LAV-i% was significantly lower in group A (those who received SGLT2 inhibitors) compared to group B (those who did not receive SGLT2 inhibitors), both in absolute terms and relative terms. In the same way, LAS absolute and relative % change showed a significant improvement in the study group compared to control. After adjusting for all correlates, it was found that adding SGLT-2 to the standard treatment resulted in reduction of the risk of MACE by 32% (AOR= 0.678, 95% CI; 0.071 – 0.984, p=0.043) compared with those treated with the standard regimen. Conclusion: the addition of SGLT-2I to patients’ existing guideline-directed medical therapy for non-valvular paroxysmal AF was found to be independently associated with reduction in the short-term adverse effects of the disease. | ||
| Keywords | ||
| Keywords: AF; SGLT2; MACE; Efficacy | ||
|
Statistics Article View: 84 PDF Download: 11 |
||
